- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00506675
Combined Patching-Atropine for Residual Amblyopia (ATS11)
A Randomized Trial to Evaluate Combined Patching-Atropine for Residual Amblyopia
This study is designed to evaluate the effectiveness of treatment of residual amblyopia in children ages 3 to < 10 years with visual acuity of 20/32 to 20/63 in the amblyopic eye. The study is a randomized clinical trial comparing intensive treatment (42 hours per week of patching plus daily atropine) with a control group that will have rapid weaning of existing treatment followed by spectacle correction only (if needed). The primary objective is to determine if this intensive treatment will improve visual acuity in patients with residual amblyopia.
The primary outcome assessment is amblyopic eye visual acuity at 10 weeks.
The primary analytic approach for the amblyopic eye acuity will be a treatment group comparison of the proportion of patients with at least two lines of visual acuity improvement.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Amblyopia is the most common cause of monocular visual impairment in both children and young and middle-aged adults. Both patching and atropine are accepted treatment modalities for the management of moderate amblyopia in children. Despite best efforts with conventional treatment, some patients fail to achieve normal visual acuity in the amblyopic eye. In a randomized trial conducted by PEDIG comparing atropine versus patching in 3 to 6 year olds with moderate amblyopia (ATS1), 261 of 402 patients (65%) had amblyopic eye visual acuity of 20/32 or worse after 6 months of treatment with patching or atropine. Beyond 6 months, treatment was at investigator discretion, and two years after randomization, 181 of 363 children (50%) still had amblyopic eye visual acuity of 20/32 or worse. In a randomized trial conducted by PEDIG comparing patching regimens, 129 of 181 patients with moderate amblyopia (71%) and 145 of 157 patients with severe amblyopia (92%) had amblyopic eye visual acuity of 20/32 or worse after 4 months of occlusion therapy. Many patients receive treatment beyond 6 months but still fail to achieve normal visual acuity in the amblyopic eye. It is unknown whether an intensive "final push" of combined treatment with daily patching and atropine will improve visual acuity in these patients. Although some clinicians prescribe simultaneous patching and atropine for selected patients, there are no published reports of its effectiveness. Also, we are not aware of reports of response to treatment of residual amblyopia.
The study has been designed as a simple trial that, other than the type of amblyopia therapy being determined through the randomization process, approximates standard clinical practice. Patients will be randomized to one of two treatment regimens:
- Intensive treatment: 42 hours per week of patching combined with daily atropine (1%)
- Control group: Weaning of the current treatment (two hours of daily patching for patients currently using patching and once weekly atropine for patients currently using atropine) for 4 weeks, then no treatment other than spectacles (if needed).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Eye Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 3 to < 10 years
- Amblyopia associated with strabismus, anisometropia, or both
- Visual acuity in the amblyopic eye between 20/32 and 20/63 inclusive
- Visual acuity in the sound eye 20/32 or better and inter-eye acuity difference >= 2 logMAR lines
Current/previous treatment with patching and/or atropine subject to the following stipulations:
- No simultaneous treatment with patching and atropine in the past 6 months
- No prior use of atropine in combination with the sound eye spectacle lens reduced by more than 1.50 D
Maximum level of any previous treatment:
- Patching: up to 42 hours per week (averaging 6 hours daily)
- Atropine: up to once daily
- Current treatment with 42 hours per week patching or daily atropine
No improvement in best-corrected amblyopic eye visual acuity between two consecutive visits at least 6 weeks apart using the same testing method and optimal spectacle correction (if needed), with no improvement defined as follows:
- No lines of improvement
- For patients tested using E-ETDRS, letter score that is no more than 4 letters improved
- Wearing spectacles with optimal correction (if applicable)
- Investigator ready to wean or stop treatment
Exclusion Criteria:
- Current vision therapy or orthoptics
- Ocular cause for reduced visual acuity
- Prior intraocular or refractive surgery
- Strabismus surgery planned within 10 weeks
- Known allergy to atropine or other cycloplegic drugs
- Known skin reactions to patch or bandage adhesives
- Down Syndrome present
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intensive
42 hours per week of patching combined with atropine (1%) once daily in the sound eye, with spectacle correction (if needed)
|
42 hours per week of patching
Other Names:
daily atropine (1%)
two hours of daily patching for 4 weeks, then no treatment
Other Names:
once weekly atropine for 4 weeks, then no treatment
|
Active Comparator: Weaning
For patients currently patching, reduce patching to two hours daily for four weeks, then no treatment thereafter except spectacle correction (if needed).
For patients currently using atropine, reduce atropine to once weekly for 4 weeks, then no treatment thereafter except spectacle correction (if needed)
|
42 hours per week of patching
Other Names:
daily atropine (1%)
two hours of daily patching for 4 weeks, then no treatment
Other Names:
once weekly atropine for 4 weeks, then no treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks
Time Frame: 10 Weeks
|
Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to <7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to <10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).
|
10 Weeks
|
Mean (SD) Distribution of Visual Acuity at 10 Weeks
Time Frame: 10 Weeks
|
Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to <7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to <10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).
|
10 Weeks
|
Distribution of Amblyopic Eye Visual Acuity Change From Baseline to 10 Weeks
Time Frame: baseline to 10 Weeks
|
Change in logMAR from baseline to 10 weeks was calculated, with positive difference indicating improvement.
Note one logMAR line = 5 letters or one Snellen line equivalent.
|
baseline to 10 Weeks
|
Mean (SD) Change in Visual Acuity in the Amblyopic Eye at the 10 Week Primary Outcome Exam
Time Frame: baseline to 10 Weeks
|
Change in logMAR from baseline to 10 weeks was calculated, with positive difference indicating improvement.
Note one logMAR line = 5 letters or one Snellen line equivalent.
|
baseline to 10 Weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Eye Diseases
- Neurologic Manifestations
- Sensation Disorders
- Vision Disorders
- Amblyopia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Mydriatics
- Atropine
Other Study ID Numbers
- NEI-135
- 2U10EY011751 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amblyopia
-
Universitat Politècnica de CatalunyaParc Sanitari Sant Joan de Déu; Hospital Mutua de TerrassaCompletedAmblyopia | Anisometropic Amblyopia | Strabismic Amblyopia | Amblyopia Occlusion | Unilateral AmblyopiaSpain
-
Vedea Healthware BVElisabeth-TweeSteden Ziekenhuis; Jeroen Bosch Ziekenhuis; Health Holland; Oogziekenhuis... and other collaboratorsRecruitingAmblyopia | Amblyopia, Anisometropic | Amblyopia StrabismicNetherlands
-
Universitat Politècnica de CatalunyaHospital Mutua de TerrassaCompletedAmblyopia | Anisometropic Amblyopia | Strabismic AmblyopiaSpain
-
Alaska Blind Child DiscoveryCompletedStrabismus | Strabismic Amblyopia | Refractive AmblyopiaUnited States
-
Baylor College of MedicineActive, not recruitingHyperopia | High Myopia | Anisometropia | Amblyopia Isometropic | Amblyopia Bilateral | High AstigmatismUnited States
-
Medical University of ViennaRecruitingAmblyopia ex Strabismus | Amblyopia ex AnisometropiaAustria
-
National Cheng-Kung University HospitalChang Gung Memorial HospitalCompletedAmblyopia | Amblyopia, Anisometropic
-
Shahid Beheshti University of Medical SciencesUnknownThe New Treatment in Amblyopia TherapyIran, Islamic Republic of
-
University of BaselUniversity Medical Center NijmegenWithdrawnStrabismic Amblyopia
-
Wenzhou Medical UniversityUnknown
Clinical Trials on Patching
-
City, University of LondonImperial College LondonCompleted
-
Washington University School of MedicineCompletedCentral Serous Retinopathy (CSR)United States
-
The Hospital for Sick ChildrenCompleted
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Pediatric Eye Disease Investigator GroupWithdrawnRefractive Errors | Anisometropic Amblyopia
-
Retina Foundation of the SouthwestRecruiting
-
NovaSightActive, not recruiting
-
Shanghai Eye Disease Prevention and Treatment CenterUnknownAmblyopia, Anisometropic
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Pediatric Eye Disease Investigator GroupCompleted
-
University of RochesterRecruitingExotropiaUnited States, Italy, Canada, India, Israel